MALVERN, Pa., April 26, 2016 (GLOBE NEWSWIRE) — BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the first quarter ended March 31, 2016.
The Research Division of BioTelemetry
BioTelemetry Research, formerly Cardiocore, is an industry leader in clinical trials testing services, monitoring, data, and scientific consulting. Our comprehensive offerings provide global clients with world-leading technology, data management, and consulting services, streamlining the clinical trials process, and ensuring optimal research performance.
Every day, BioTelemetry Research’s global clinical trials services team meets the demands of Phase I–IV studies for the world’s largest pharmaceutical organizations, specialty pharmaceutical firms, emerging biotechnology companies, and medical device manufacturers. Providing a full range of centralized clinical trials testing modalities for both safety and endpoint evaluation, our core offerings include:
- Global Cardiovascular Monitoring for Clinical Trials
- Advanced Imaging Services for Clinical Trials
- Respiratory Testing Alliance for Clinical Trials
Comprehensive Testing Services for Clinical Trials
Today as BioTelemetry Research, we are a member of the world’s largest cardiac data network — processing over 2 billion heartbeats a day, while supporting more than 20,000 sites and 30,000 devices monthly, as well as monitoring over 500,000 patients a year. In addition to industry-leading global cardiovascular monitoring, we have now expanded our clinical trial services in two important areas: advanced imaging services for oncology, neurologic, cardiac, and musculoskeletal imaging, and a global alliance for respiratory testing and clinical trials expertise.
Blood Pressure Evaluation During Early Phase Trials
More attention is being paid to blood pressure (BP) effects in new chemical entities under development for non-hypertension indications, especially when these are not anticipated and not thoroughly defined during drug development.
BioTelemetry Research’s exclusive offering, EvriBeat, an advanced alternative method to Thorough QT studies for assessing cardiac safety in early human trials.